Donanemab - Alzheimers disease
You are here : Home > Formulary Search > Donanemab - Alzheimers disease
Documentation
- No records returned.
PAD Profile
This drug has not yet been assessed for formulary status.
If a patient is accessing non-NHS supplies of this medication, refer to the NHSE information here (for a similar drug called lecanemab) which provides advice on potential adverse effects.
Committee Recommendations (1)
This drug has not yet been assessed for formulary status.
If a patient is accessing non-NHS supplies of this medication, refer to the NHSE information here (for a similar drug called lecanemab) which provides advice for clinical teams who may be asked to support referrals for private treatment or otherwise assess, advise and possibly treat a small number of patients who could present with potential adverse treatment effects, including symptomatic Amyloid-Related Imaging Abnormalities (ARIA).
This drug not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.
NICE are due to publish guidance on this drug in March 2025 and this will be considered by the APC within 90 days of publication.